ВИРУС ПАПИЛЛОМЫ ЧЕЛОВЕКА И РАК РОТОГЛОТКИ: СОВРЕМЕННЫЕ ВЗГЯДЫ НА КЛИНИКО-ЭПИДЕМИОЛОГИЧЕСКИЕ И ПРОГНОСТИЧЕСКИЕ АСПЕКТЫ
Ключевые слова:
рак ротоглотки; вирус папилломы человека; ВПЧ-ассоциированный рак; эпидемиология; канцерогенез; p16; диагностика; прогноз; персонализированное лечениеАннотация
Цель: Оценить влияние комбинированной схемы лечения на маркеры воспаления и метаболические параметры у пациентов IV стадии рака яичников, эндометрия и шейки матки, находящихся в состоянии прекахексии. Материалы и методы: Проведено проспективное Аннотация: Рак ротоглотки в последние десятилетия характеризуется выраженным изменением эпидемиологического профиля, обусловленным ростом доли вирус папилломы человека (ВПЧ)-ассоциированных форм. ВПЧ-позитивный рак ротоглотки в настоящее время рассматривается как самостоятельный клинико-биологический подтип опухолей головы и шеи, отличающийся по факторам риска, морфологическим характеристикам, клиническому течению и прогнозу. В обзоре обобщены современные данные о распространённости ВПЧ-ассоциированного рака ротоглотки, биологии вируса и механизмах ВПЧ-индуцированного канцерогенеза, клинико-морфологических особенностях и диагностических подходах. Особое внимание уделено прогностическому значению ВПЧ-статуса, роли генотипа вируса, вирусной нагрузки и физического статуса ВПЧ в формировании клинических исходов, а также современным концепциям персонализированного лечения и деэскалации терапии. Показано, что интеграция клинических, морфологических и молекулярных характеристик ВПЧ позволяет углубить прогностическую стратификацию больных и оптимизировать лечебную тактику. Подчёркивается необходимость проведения регионально ориентированных исследований для уточнения эпидемиологических и клинико-прогностических особенностей ВПЧ-ассоциированного рака ротоглотки.
Библиографические ссылки
Лопатин А.С. Эндоскопия верхних дыхательных путей. Москва: ГЭОТАР-Медиа; 2017. С. 198–223.
Ang K.K., Harris J., Wheeler R., et al. HPV and survival of patients with OPSCC. N Engl J Med. 2010;363:24–35.
Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine. 2010;363:24–35.
Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., zur Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–79.
Boscolo-Rizzo P., Pawlita M., Holzinger D. From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treatment Reviews. 2016;42:24–29.
Branstetter B.F. IV, Blodgett T.M., Zimmer L.A., et al. Head and neck malignancy: PET/CT imaging. Radiology. 2005;237(2):404–414.
Castellsagué X., Alemany L., Quer M., et al. HPV involvement in head and neck cancers: comprehensive assessment. The Lancet Oncology. 2016;17(7):982–992.
Chaturvedi A.K., Engels E.A., Pfeiffer R.M., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology. 2011;29(32):4294–4301.
College of American Pathologists, ASCO, AMP. Human papillomavirus testing in head and neck carcinomas. Archives of Pathology & Laboratory Medicine. 2018;142(5):559–597.
D’Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of HPV and OPSCC. N Engl J Med. 2007;356:1944–1956.
Dahlgren L., Mellin H., Wangsa D., et al. Comparative genomic profiling of HPV-positive OPSCC. International Journal of Cancer. 2003;107(5):847–852.
Doorbar J., Quint W., Banks L., Bravo I.G., Stoler M., Broker T.R., Stanley M.A. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–F70.
Dyson N., Howley P.M., Münger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934–937.
El-Naggar A.K., Chan J.K.C., Grandis J.R., Takata T., Slootweg P.J. (eds.) WHO Classification of Head and Neck Tumours. 4th ed. Lyon: IARC; 2017. p. 119–141.
Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with HPV-positive OPSCC. Journal of the National Cancer Institute. 2008;100(4):261–269.
Fakhry C., Zhang Q., Nguyen-Tan P.F., et al. Human papillomavirus and response to therapy. Journal of Clinical Oncology. 2014;32(30):3365–3373.
Gillison M.L., Chaturvedi A.K., Anderson W.F., Fakhry C. Epidemiology of human papillomavirus–positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235–3242.
Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between HPV and a subset of head and neck cancers. Journal of the National Cancer Institute. 2000;92(9):709–720.
Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., Zahurak M.L., Daniel R.W., Viglione M., Symer D.E., Shah K.V., Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute. 2000;92(9):709–720.
Gillison M.L., Zhang Q., Jordan R., et al. Tobacco smoking and increased risk of death in HPV-positive OPSCC. Journal of Clinical Oncology. 2012;30(17):2102–2111.
Goldenberg D., Begum S., Westra W.H., et al. Cystic lymph node metastasis in HPV-related OPSCC. Archives of Otolaryngology – Head & Neck Surgery. 2008;134(6):654–660.
Hauck F., Domschke C., et al. Recommendations for HPV testing. Virchows Archiv. 2014;465(3):251–261.
Holzinger D., et al. Biomarkers and prognosis in HPV-driven OPSCC. Journal of Clinical Oncology. 2012;30(26):3075–3083.
Holzinger D., et al. Viral transcription and prognosis in OPSCC. Clinical Cancer Research. 2012;18(18):4986–4997.
Holzinger D., Flechtenmacher C., Henfling N., et al. HPV DNA load and survival. Journal of Clinical Oncology. 2012;30(26):3075–3083.
Huang S.H., Xu W., Waldron J., et al. Refining prognosis in HPV-related OPSCC. Journal of Clinical Oncology. 2015;33(8):836–845.
Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiology, Biomarkers & Prevention. 2005;14(2):467–475.
Lechner M., Liu J., Masterson L., Fenton T.R. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nature Reviews Clinical Oncology. 2022;19(5):306–327.
Lewis J.S. Jr. p16 Immunohistochemistry as a surrogate marker of HPV. Head & Neck Pathology. 2012;6(Suppl 1):S75–S82.
Lewis J.S. Jr., Beadle B., Bishop J.A., Chernock R.D., Colasacco C., Lacchetti C., et al. Human papillomavirus testing in head and neck carcinomas: guideline. Archives of Pathology & Laboratory Medicine. 2018;142(5):559–597.
Lydiatt W.M., Patel S.G., O’Sullivan B., Brandwein M.S., Ridge J.A., Migliacci J.C., Loomis A.M., Shah J.P. Head and neck cancers—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians. 2017;67(2):122–137.
Mantovani F., Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 2001;20(54):7874–7887.
Marur S., Li S., Cmelak A.J., et al. E1308 trial. Journal of Clinical Oncology. 2017;35(5):490–497.
Masterson L., Moualed D., Masood A., et al. De-escalation treatment protocols. Oral Oncology. 2014;50(5):354–360.
Mehanna H., Beech T., Nicholson T., El-Hariry I., McConkey C., Paleri V., Roberts S. Prevalence of human papillomavirus in oropharyngeal and non-oropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. The Lancet Oncology. 2013;14(7):622–629.
Mehanna H., Wong W.L., McConkey C.C., et al. PET-CT surveillance versus neck dissection. New England Journal of Medicine. 2016;374:1444–1454.
Mellin H., Dahlgren L., Munck-Wikland E., et al. Human papillomavirus load in OPSCC. International Journal of Cancer. 2002;102(2):152–158.
Mirabello L., Clarke M.A., Nelson C.W., Dean M., Wentzensen N., Yeager M., et al. The intersection of HPV epidemiology, genomics and mechanistic studies of HPV-mediated carcinogenesis. Viruses. 2018;10(2):80.
Mirghani H., Amen F., Moreau F., et al. Do high-risk human papillomaviruses cause all oropharyngeal squamous cell carcinomas? Cancer Treatment Reviews. 2015;41(6):480–486.
Mirghani H., Blanchard P. Treatment de-escalation for HPV-driven OPSCC. Clinical and Translational Radiation Oncology. 2018;8:4–11.
Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nature Reviews Cancer. 2010;10(8):550–560.
Münger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., Huh K. Mechanisms of human papillomavirus-induced oncogenesis. Journal of Virology. 2004;78(21):11451–11460.
Ndon S., et al. HPV-associated oropharyngeal cancer: global patterns. Cancers (Basel). 2023;15(16):4080.
Ng S.H., Yen T.C., Liao C.T., et al. 18F-FDG PET and CT/MRI in staging of head and neck cancer. Journal of Nuclear Medicine. 2005;46(12):1902–1908.
Nulton T.J., Kim N.K., DiNardo L.J., et al. HPV integration and its implications in OPSCC. Journal of Virology. 2017;91(4):e02056-16.
O’Sullivan B., Huang S.H., Perez-Ordonez B., et al. Outcomes of HPV-related OPSCC. Journal of Clinical Oncology. 2012;30(19):2109–2116.
O’Sullivan B., Huang S.H., Siu L.L., et al. Deintensification candidate subgroups. Journal of Clinical Oncology. 2013;31(5):543–550.
O’Sullivan B., Huang S.H., Su J., Garden A.S., Sturgis E.M., Dahlstrom K., Lee N., Riaz N., Pei X., Koyfman S.A., Adelstein D., Rosenthal D.I., Ang K.K. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S). Journal of Clinical Oncology. 2016;34(36):4350–4357.
Parfenov M., Pedamallu C.S., Gehlenborg N., et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Genome Research. 2014;24(4):646–657.
Podvinec M., Steiner W., Ambrosch P., Pfister D.G. Diagnostic approaches to oropharyngeal cancer. Head & Neck. 2012;34(9):1202–1210.
Poeta M.L., Manola J., Goldwasser M.A., et al. TP53 mutations and survival. New England Journal of Medicine. 2007;357:2552–2561.
Pytynia K.B., Dahlstrom K.R., Sturgis E.M. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncology. 2014;50(5):380–386.
Reuschenbach M., Kansy K., Garbe K., et al. Lack of evidence of HPV DNA integration in OPSCC associated with favorable outcome. International Journal of Cancer. 2015;137(6):1357–1365.
Rietbergen M.M., Brakenhoff R.H., Bloemena E., et al. Molecular characterization of HPV-positive OPSCC. International Journal of Cancer. 2013;132(10):2367–2375.
Rumgay H., Colombet M., Mery L., et al. Global incidence of lip, oral cavity and pharyngeal cancers by subsite in 2022. CA: A Cancer Journal for Clinicians. 2026;76(1).
Sano T., Oyama T., Kashiwabara K., et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential. Pathology International. 1998;48(8):580–585.
Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129–1136.
Schmitt M., Dalstein V., Waterboer T., et al. HPV RNA detection in OPSCC. International Journal of Cancer. 2011;128(4):832–838.
Seiwert T.Y., Foster C.C., Blair E.A., et al. De-escalated chemoradiation therapy. Journal of Clinical Oncology. 2019;37(22):1909–1918.
Sinha P., Thorstad W.T., Nussenbaum B., et al. Distant metastases in HPV-positive OPSCC. Head & Neck. 2012;34(6):742–747.
Snietura M., Jaworska M., Pigłowski W., et al. Viral load and physical status of HPV16 in OPSCC. Head & Neck. 2011;33(10):1439–1447.
Syrjänen S. HPV infections and tonsillar carcinoma. Journal of Clinical Pathology. 2004;57(5):449–455.
Tan Y.J., et al. Prevalence of HPV-associated OPSCC: meta-analysis. Acta Med Marisiensis. 2023;69(2):77–92.
Tan Y.J., et al. Prevalence of human papillomavirus-associated oropharyngeal squamous cell carcinoma: meta-analysis with method-dependent estimates. Acta Medica Marisiensis. 2023;69(2):77–92.
Ukpo O.C., Flanagan J.J., Ma X.J., et al. High-risk HPV RNA in situ hybridization assay. American Journal of Surgical Pathology. 2011;35(5):657–663.
Weinstein G.S., O’Malley B.W. Jr. Transoral robotic surgery. Annals of Otology, Rhinology & Laryngology. 2007;116(1):19–23.
Wentzensen N., Vinokurova S., von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes. Cancer Research. 2004;64(11):3878–3884.
Westra W.H. The morphologic profile of HPV-related head and neck SCC. Head & Neck Pathology. 2009;3(1):1–8.
